To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Perioperative duloxetine for postoperative outcomes in Patients With Depression

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2025

Perioperative duloxetine for postoperative outcomes in Patients With Depression

Vol: 307| Issue: 2| Number:58| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Perioperative duloxetine improves postoperative outcomes after anterior talofibular ligament repair for chronic lateral ankle instability for patients with depression: A prospective randomized clinical trial.

Orthop Traumatol Surg Res . 2024 Nov;110(7):103837.

Contributing Authors:
HHG Zaid X Hua Y Huang B Chen Z Jichuan G Yang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred twenty patients with chronic lateral ankle instability and preoperative depression were randomized to receive perioperative duloxetine (n=60) or placebo (n=60) starting one day before ATFL repair and continuing for six weeks postoperatively. The primary outcome was postoperative pain intensity and opioid consumption. Secondary outcomes included time to first rescue analgesic, patient s...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue